Arsenic Trioxide Controls the Fate of the PML-RARα Oncoprotein by Directly Binding PML
2010/04/08 by Xiaowei Zhang, Xiao-Wei Zhang, Xiao-Jing Yan +34 · 25 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Retinoids in leukemia and cellular processes #Acute Myeloid Leukemia Research #Biotin and Related Studies
paper · doi:10.1126/science.1183424
Abstract
Arsenic, an ancient drug used in traditional Chinese medicine, has attracted worldwide interest because it shows substantial anticancer activity in patients with acute promyelocytic leukemia (APL). Arsenic trioxide (As2O3) exerts its therapeutic effect by promoting degradation of an oncogenic protein that drives the growth of APL cells, PML-RARalpha (a fusion protein containing sequences from the PML zinc finger protein and retinoic acid receptor alpha). PML and PML-RARalpha degradation is triggered by their SUMOylation, but the mechanism by which As2O3 induces this posttranslational modification is unclear. Here we show that arsenic binds directly to cysteine residues in zinc fingers located within the RBCC domain of PML-RARalpha and PML. Arsenic binding induces PML oligomerization, which increases its interaction with the small ubiquitin-like protein modifier (SUMO)-conjugating enzyme UBC9, resulting in enhanced SUMOylation and degradation. The identification of PML as a direct target of As2O3 provides new insights into the drug's mechanism of action and its specificity for APL.
Cited by
- Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. [europepmc]
- Anticancer activity of metal complexes: involvement of redox processes. [europepmc]
- The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA. [europepmc]
- Sequential posttranslational modifications program FEN1 degradation during cell-cycle progression. [europepmc]
- The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies. [europepmc]
- Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. [europepmc]
- Differential Roles of PML Isoforms. [europepmc]
- Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. [europepmc]
- Regulation of transcription factor activity by interconnected post-translational modifications. [europepmc]
- Oxidative stress-induced assembly of PML nuclear bodies controls sumoylation of partner proteins. [europepmc]
- Heavy metals and metalloids as a cause for protein misfolding and aggregation. [europepmc]
- Drugging MYCN through an allosteric transition in Aurora kinase A. [europepmc]
- Molecular Connections between Cancer Cell Metabolism and the Tumor Microenvironment. [europepmc]
- Pharmacological GLI2 inhibition prevents myofibroblast cell-cycle progression and reduces kidney fibrosis. [europepmc]
- SUMOylation-Mediated Regulation of Cell Cycle Progression and Cancer. [europepmc]
- Targeting Transcription Factors in Cancer. [europepmc]
- ALTernative Telomere Maintenance and Cancer. [europepmc]
- PML: Regulation and multifaceted function beyond tumor suppression. [europepmc]
- Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. [europepmc]
- Protein Degradation and the Pathologic Basis of Disease. [europepmc]
- Chlorogenic acid effectively treats cancers through induction of cancer cell differentiation. [europepmc]
- SUMO: From Bench to Bedside. [europepmc]
- Natural Products in Cancer Therapy: Past, Present and Future. [europepmc]
- Targeting p53 pathways: mechanisms, structures, and advances in therapy. [europepmc]
- Hedgehog signaling in tissue homeostasis, cancers, and targeted therapies. [europepmc]
Related